Inhibikase Therapeutics, Inc (IKT) insider trading
Every open-market stock purchase and sale by Inhibikase Therapeutics, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- Insiders bought $3M over the last 12 months (1 buy).
- Last insider buy: Sands Capital Life Sciences Pulse Fund II L.P. (10% owner), $3M, 10 months ago.
Last 12 months: insiders bought $3M (1 buy) and sold $0 (0 sales). Last close $1.63 on Jun 4, 2026.
Recent IKT insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Jun 26, 2026 | David Canner (Insider) | Bought (not open market) | — |
| Jun 26, 2026 | Amit Munshi (Insider) | Bought (not open market) | — |
| Jun 26, 2026 | Arvind Kush (Insider) | Bought (not open market) | — |
| Jun 26, 2026 | Roberto Bellini (Insider) | Bought (not open market) | — |
| Jun 26, 2026 | Dennis N Berman (Insider) | Bought (not open market) | — |
| Jun 26, 2026 | Vincent Aurentz (Insider) | Bought (not open market) | — |
| Feb 21, 2026 | Amit Munshi (Insider) | Sold (not open market) | — |
| Feb 21, 2026 | Christopher Cabell (President) | Sold (not open market) | — |
| Feb 21, 2026 | Vincent Aurentz (Insider) | Sold (not open market) | — |
| Jan 5, 2026 | Mark T Iwicki (CEO) | Bought (not open market) | — |
| Jan 5, 2026 | Christopher Cabell (President) | Bought (not open market) | — |
| Jan 5, 2026 | David McIntyre (CFO) | Bought (not open market) | — |
| Nov 21, 2025 | Sands Capital Life Sciences Pulse Fund II L.P. (10% owner) | Bought | $3M |
Who's trading IKT
- Dennis N Berman, Insider: other filings, last Jun 26, 2026
- Amit Munshi, Insider: other filings, last Jun 26, 2026
- Roberto Bellini, Insider: other filings, last Jun 26, 2026
- David Canner, Insider: other filings, last Jun 26, 2026
- Vincent Aurentz, Insider: other filings, last Jun 26, 2026
- Arvind Kush, Insider: other filings, last Jun 26, 2026
- Christopher Cabell, President: other filings, last Feb 21, 2026
- Mark T Iwicki, CEO: other filings, last Jan 5, 2026
- David McIntyre, CFO: other filings, last Jan 5, 2026
- Sands Capital Life Sciences Pulse Fund II L.P., 10% owner: bought $3M (1 buy), last Nov 21, 2025
Get free alerts when an insider at Inhibikase Therapeutics, Inc files a new trade →